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A B S T R A C T
In polyglutamine diseases, an abnormally elongated polyglutamine tract results in protein misfolding
and accumulation of intracellular aggregates. The length of the polyglutamine expansion correlates with
the tendency of the mutant protein to aggregate, as well as with neuronal toxicity and earlier disease
onset. Although currently there is no effective cure to prevent or slow down the progression of these
neurodegenerative disorders, increasing the clearance of mutant proteins has been proposed as a
potential therapeutic approach. The ubiquitin–proteasome system and autophagy are the two main
degradative pathways responsible for eliminating misfolded and unnecessary proteins in the cell. We
will review some of the studies that have proposed autophagy as a strategy to reduce the accumulation
of polyglutamine-expanded protein aggregates and protect against mutant protein neurotoxicity. We
will also discuss some of the currently known mechanisms that induce autophagy, which may be
beneﬁcial for the treatment of these and other neurodegenerative disorders.
 2011 Elsevier Ltd. 
Abbreviations: HD, Huntington’s disease; SCA, spinocerebellar ataxia; DRPLA, Denatorubral-pallidoluysian atrophy; SBMA, spinal and bulbar muscular atropy; Htt,
Huntingtin; UPS, ubiquitin–proteasome system; HDL-2, Huntington’s disease-like 2; IBs, inclusion bodies; RNAi, RNA interference; Atg, autophagy-related genes; ER,
endoplasmic reticulum; PI3K, phosphatidylinositol 3-kinase; JNK1, c-Jun N-terminal protein kinase 1; PE, phosphatidylethanolamine; SNAREs, soluble N-ethylmaleimide-
sensitive factor attachment protein receptors; mTOR, mammalian target of rapamycin; PI-3-P, phosphatidylinositol-3-phosphate; ROS, reactive oxygen species; IP3, inositol-
1,4,5-triphosphate; IP3R, IP3 receptors; cAMP, cyclic AMP; IMPase, inositol monophosphatase; GSK3b, glycogen synthase kinase-3 b; I1R, imidazoline-1-receptor; SMERs,
small molecule enhancers of rapamycin; SMIRs, small molecule inhibitors of rapamycin.
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1. Introduction
Protein misfolding and subsequent aggregation are common
features in many late-onset neurodegenerative disorders, such as
Parkinson’s disease, Alzheimer’s disease and other tauopathies.
The presence of these protein aggregates in brains of patients has
been correlated with neuronal cell death and with earlier onset and
increased symptom severity (Soto and Estrada, 2008). These
disorders are commonly referred to as proteinopathies and include
a group of conditions in which the aggregated proteins are encoded
by genes containing trinucleotide repeat expansions. When this
trinucleotide encodes the amino acid glutamine, it results in
proteins with abnormally extended polyglutamine tracts and the
disorders are hence termed poluglutamine disorders (Orr and
Zoghbi, 2007). These expanded regions confer the protein the
tendency to aggregate when the number of repeats exceeds a
normal physiological number. Whether aggregated forms of these
proteins and their intermediate forms represent toxic or protective
species has been a matter of debate (Takahashi et al., 2010).
However, the mutant proteins cause disease via a toxic gain-of-
function mechanism, and it is generally accepted that degradation
of polyglutamine-containing proteins would be a beneﬁcial
therapeutic approach for the treatment of these diseases. Two
main degradative pathways are responsible for clearance of
misfolded and unnecessary proteins in the cell: the ubiquitin–
proteasome system (UPS) and autophagy (Rubinsztein, 2006).
While oligomierised forms of proteins are inefﬁciently degraded by
the proteasome, they can be targeted for degradation by
autophagy, a lysosomal degradative pathway. In this review, we
will focus on the role of autophagy in polyglutamine disorders,
mainly Huntington’s disease, the most prevalent of these condi-
tions. We will review some of the increasing number of studies
showing the potential beneﬁt of upregulating autophagy for
reducing the presence of these protein aggregates and therefore for
the treatment of these and, other aggregate-prone protein
disorders. We will also discuss different pharmacological
approaches that, through autophagy stimulation, provide protec-
tion in polyglutamine neurodegenerative disorders.
2. Polyglutamine diseases
2.1. Genetics of CAG repeat disorders
Polyglutamine diseases consist of a group of ten autosomal
dominant neurodegenerative disorders, which include Hunting-
ton’s disease (HD), dentatorubral-pollidoluysian atrophy (DRPLA),
spinal and bulbal muscular atrophy (SBMA), several types of
spinocerebellar ataxias (SCAs), and the more recently proposed
Huntington’s disease-like 2 (HDL-2) (Orr and Zoghbi, 2007;
Wilburn et al., 2011). Despite the large spectrum of neurological,
psychiatric and motor symptoms present in these conditions, they
all lead to chronic, slow progressive diseases affecting the central
nervous system, for which no cure is available to date.
These disorders share a common genetic etiology, in which genes
contain a repetitive DNA sequence consisting of the trinucleotide
CAG, coding for the amino acid glutamine. This CAG rich region is
unstable and tends to expand from one generation to the next
(La Spada et al., 1994). As a consequence, the resulting protein
contains an abnormal extension of polyglutamines that leads to
individuals developing the disease when the repeats exceed a
certain number. The threshold differs between diseases and is
usually around 40 glutamines (Semaka et al., 2006; Langbehn et al.,
2010). However, in the case of SCA6, an expansion between 18 and
33 glutamines in the CACNA1A gene, which encodes the alpha1A
subunit of the P/Q-type voltage-gated calcium channel, is sufﬁcient
to cause the disease (Riess et al., 1997). Although in all known
polyglutamine disorders there is a direct correlation between the
severity of the disease and the polyglutamine length, the molecular
and cellular mechanisms underlying the pathology are not fully
understood (Orr, 2001). Moreover, the population of target neurons
and the symptoms differ from one disease to the other, indicating
that the nature of the affected protein as well as other genetic factors
contribute to the progression of the disease and speciﬁcity (Gatchel
and Zoghbi, 2005).
Proteins involved in CAG repeat disorders have crucial cellular
activities, and are involved in different functions such as
transcription, signalling or transport. And it is therefore possible
that some aspects of the disease phenotype arise from a loss-of-
function of the wild-type protein. However, mice heterozygous for
Htt deletion do not mimic HD pathology, similar to the lack of
evidence of ataxia or neurodegeneration in ataxin-1-null mice
(Duyao et al., 1995; Zeitlin et al., 1995; Matilla et al., 1998). In
contrast, experimental evidence suggests that that these diseases
result mainly from a gain-of-function of the protein carrying a CAG
expansion. Transgenic expression of the ﬁrst exon or the full length
Htt protein with an expanded polyglutamine produces pathologi-
cal and phenotypic features of HD (Mangiarini et al., 1996;
Hodgson et al., 1999). Moreover, a mouse model ectopically
expressing a polyglutamine repeat presented a neurotoxic
phenotype, characteristic of polyglutamine disorders, as well as
the presence of intraneuronal protein aggregates (Ordway et al.,
1997), suggesting that the polyglutamine repeat itself is sufﬁcient
to render neuronal cell death. A recent study has suggested that
any contribution of a loss-of-function mechanism to HD may be
minimal. Transcriptional regulation was compared between cells
expressing a polyglutamine-expanded Htt and Huntingtin-null
cells, and there was no overlap in the genes regulated in each
condition, suggesting that a loss of the wild-type Htt does not
contribute to the pathology of HD (Jacobsen et al., 2011).
2.2. Properties and toxicity of polyglutamine aggregates
Similar to other proteinopathies, the presence of intraneuronal
protein aggregates is a common feature in the brains of patients
suffering from CAG repeat disorders. Although the polyglutamine
tract is common to all of these disorders and is responsible for the
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aggregation of the protein, the neuronal populations and brain
areas targeted are protein-speciﬁc, suggesting an important
contribution of the surrounding protein domains, posttranslational
modiﬁcations, cleavage or cellular localization in their pathogene-
sis (Robertson and Bottomley, 2010). For instance, phosphoryla-
tion of threonine 3 in the ﬁrst exon of mutant Htt protein increases
its tendency to aggregate and cause pathology (Aiken et al., 2009).
Aggregates, also termed inclusion bodies (IBs), can be observed
intracellularly by light microscopy and are positive for compo-
nents of the ubiquitin–proteasome system as well as chaperones.
IBs present an amyloid structure similar to a-synuclein or Ab
peptide deposits, and this has been conﬁrmed using anti-amyloid
antibodies, thioﬂavin binding or Congo red birefringence. In the
folding process between the soluble monomeric forms and the IBs,
however, a variety of intermediate oligomeric forms have been
described, including spherical or annular structures, amorphous
forms, protoﬁbrils and ﬁbrils (reviewed in Hands and Wyttenbach,
2010).
The role of these protein aggregates in the disease is controver-
sial. Whether aggregates or the intermediate forms represent toxic,
protective or just incidental species is currently unclear – indeed,
there may be multiple species mediating toxicity via distinct
mechanisms. A protective role of protein inclusions, possibly by
sequestering potentially more toxic intermediate oligomeric forms
of the polyglutamine-containing protein, has been suggested in
mouse models of HD (Arrasate et al., 2004), SCA1 (Watase et al.,
2002) or SCA7 (Yoo et al., 2003). Along these lines, work from
Takahashi et al. (2008) in neuronally differentiated cells showed that
soluble oligomers of polyglutamines are more toxic than monomeric
forms or the IBs. However, there is also evidence supporting a
deleterious effect of protein inclusions. For instance, it has been
shown that aggregate formation correlates with apoptotic cell death
in cultured cells (Hackam et al., 1998; Lunkes and Mandel, 1998) and
in a mouse model of HD (Yamamoto et al., 2000). In general, it is
accepted that, although the nature of the toxic forms is not known,
the propensity to aggregate is related to neuronal toxicity, which is
supported by two facts: First, the length of the polyglutamine tract
directly correlates with the tendency to aggregate, and second, the
number of polyglutamines determines the severity of the disease
and earlier age of onset (Perutz and Windle, 2001).
Consequently, decreasing the levels of expanded polyglutamine
proteins has been pursued as a therapeutic strategy aimed to
reduce the presence of toxic forms of aggregate-prone proteins.
Strategies directed towards decreasing protein levels by affecting
protein synthesis are being developed by targeting their expres-
sion using RNA interference. Since 2005, different HD mouse
models, RNAi types and delivery methods have been tested with
successful improvements in HD phenotypes and therefore this
represents a promising human therapeutic strategy (Harper et al.,
2005; Rodriguez-Lebron et al., 2005; Boudreau et al., 2009).
However, several toxicity issues still need to be addressed related
to the off-target effects of RNAi oligonucleotides and the effects of
long-term treatments. Also, in the heterozygous state it needs to be
considered what the negative implications of simultaneously
silencing both mutant and wild-type genes are, as the con-
sequences of this are not entirely understood (reviewed in Harper,
2009). An alternative strategy to avoid the accumulation of toxic
proteins consists of accelerating their degradation, which, if
speciﬁcally targeted to the mutant form of the protein, could
represent a beneﬁcial and safe therapeutic approach.
2.3. Mechanisms for clearance of polyglutamine proteins: the UPS and
autophagy
In eukaryotic cells, two main pathways are necessary for
degradation of misfolded proteins: the ubiquitin–proteasome
system (UPS) and autophagy. In the former process, the 76 amino
acid protein ubiquitin is conjugated to a lysine residue on the
degradation-bound substrate via the concerted actions of three
enzymes: an activating enzyme (E1), a conjugating enzyme (E2),
and a ligase (E3). Through this pathway, soluble, short-lived
proteins are targeted to the 26S proteasome, a multisubunit
protease (Pickart, 2001).
Autophagy, on the other hand, does not necessarily involve
selective cargo recognition but it degrades long-lived intracyto-
plasmic proteins and organelles by engulfment of portions of
cytoplasm into a double-membrane vesicle called the autophago-
some. The autophagosome then fuses with the lysosome and
protein degradation occurs, as will be discussed in more detail in
Section 3 (Ravikumar et al., 2010b).
Although Htt is ubiquitinated and targeted for degradation by
the proteasome, Venkatraman et al. (2004) and Holmberg et al.
(2004) showed that the polyglutamine tract cannot be efﬁciently
cleaved by the catalytic subunit of the proteasome, thus releasing
an isolated polyglutamine tract from the proteasome, which could
constitute an even more aggregate-prone and toxic form.
The UPS is a degradative pathway that is constitutively active
under normal conditions and thus it is difﬁcult to ﬁnd mechanisms
for enhancing its activity. Recently, Lee et al. (2010a) described a
non-catalytic approach to increase proteasome activity. They
identiﬁed a small molecule that inhibited the deubiquitinating
enzyme USP14, involved in ubiquitin chain trimming. Treatment
with this compound enhanced degradation of proteins important
in neurodegeneration such as tau, TDP43 or ataxin-3 (a poly-
glutamine expanded protein causing SCA3), and could provide
novel strategies for increasing protein degradation by regulating
protein degradation by the UPS. However, enhancing degradation
by the proteasome may affect key short-lived proteins whose
levels are tightly regulated, such as p53, and thus may have
deleterious effects.
In the following sections, we will review the autophagic
machinery and how upregulation of autophagy could be beneﬁcial
in HD and other polyglutamine diseases, as well as how autophagy
homeostasis is compromised in these and other neurodegenerative
diseases. We will ﬁnally comment on novel therapeutical
strategies that have been proposed for these disorders based on
an enhancement of autophagic activity.
3. Autophagy
3.1. Introduction
Macroautophagy is a bulk degradation process conserved from
yeast to humans. Portions of cytoplasm are engulfed into a double-
membraned vesicle, the autophagosome, which is degraded by
subsequent fusion with lysosomes. While we will focus on
macroautophagy, it is worth noting that other subtypes of
autophagy exist. Chaperone-mediated autophagy degrades soluble
cytoplasmic substrates containing a KEFRQ-like pentapeptide
motif that is recognized by the chaperone heat shock cognate
protein of 70 kDa (Hsc70). The substrate is targeted to the
lysosomal membrane, where it interacts with lysosome-associated
membrane protein type 2A (LAMP2A) and is unfolded before being
translocated across the membrane for degradation within the
lysosome (Kaushik et al., 2011). Microautophagy involves invagi-
nations of the lysosomal membrane. A similar process, termed
endosomal-microautophagy occurs in late endosomes and
requires the action of endosomal sorting complex required for
transport I (ESCRT-I), ESCRT-III and Hsc70 (Sahu et al., 2011).
Macroautophagy (henceforth referred to as autophagy), on the
other hand, begins with the formation of a phagophore or pre-
autophagosomal structure, which elongates and fuses to form a
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double-membraned vesicle known as the autophagosome (Fig. 1).
Autophagosomes can fuse with endosomes to form amphisomes
(Gordon and Seglen, 1988), and eventually with lysosomes to form
autolysosomes, where the contents are degraded by lysosomal
hydrolases. This process is upregulated under starvation and stress
conditions, where it functions to liberate nutrients. For example,
immediately after birth, neonates face a period of starvation prior
to receiving nutrients through milk. During this time, autophagy is
signiﬁcantly upregulated, and newborn mice deﬁcient in autop-
hagy fail to survive (Kuma et al., 2004).
Even in basal conditions, however, autophagy can work to clear
misfolded proteins and damaged organelles. For instance, the
autophagic degradation of mitochondria – termed mitophagy by
Lemasters (2005) – protects against cell death by ridding the cell of
damaged mitochondria and thereby preventing the production of
excessive reactive oxygen species (ROS), the release of proapop-
totic proteins such as cytochrome c, and subsequent activation of
caspase 3 and 9 (Ravikumar et al., 2006; Rodriguez-Enriquez et al.,
2006; Kim et al., 2007).
In addition to performing housekeeping functions, autophagy
has several other functions, including the clearance of infectious
agents, such as Mycobacterium tuberculosis (Gutierrez et al., 2004)
and Group A Streptococcus (Nakagawa et al., 2004), aiding in
antigen presentation via major histocompatibility complex class II
(MHC II) (Lee et al., 2010b) and development (Cecconi and Levine,
2008).
3.2. Autophagy machinery
Studies in yeast have identiﬁed approximately 30 autophagy-
related (ATG) genes required for autophagy, many of which have
mammalian orthologues (Meijer et al., 2007; Xie and Klionsky,
2007). These genes are involved in various stages of the autophagy
pathway: beginning with initiation of autophagosome formation,
followed by the elongation of the membrane to a complete
autophagosome, and ending with maturation – the fusion with
lysosomes.
3.2.1. Initiation
The formation of phagophores (the precursors of autophago-
somes) begins at so-called phagophore assembly sites. The source
of membrane for the nascent phagophore is still a topic of
considerable debate. Some studies point to the endoplasmic
reticulum (ER) as a contributor to the pre-autophagosomal
structure: using various ﬂuorescence imaging techniques, Axe
et al. (2008) showed that autophagy-speciﬁc proteins accumulate
at structures termed omegasomes that are associated with the ER,
and eventually autophagosomes begin to appear. Later work using
electron microscopy and 3D tomography supports this view
(Hayashi-Nishino et al., 2009; Yla¨-Anttila et al., 2009). Meanwhile,
other groups suggest that the Golgi complex (Geng et al., 2010; van
der Vaart et al., 2010) or mitochondria (Hailey et al., 2010) act as
lipid donors. Recent work from our group has implicated the
Fig. 1. Autophagy machinery.
Autophagy is a bulk degradation process in which portions of cytoplasm are engulfed by autophagosomes and degraded by fusion with lysosomes. Current evidence suggests
that multiple compartments, including the endoplasmic reticulum, Golgi, mitochondria, and the plasma membrane may act as lipid donors to the growing phagophore, and
Atg9 has been implicated in the membrane delivery. The Beclin 1 complex regulates the formation of autophagosomes, and includes autophagy-related proteins (shown in
dark blue), and proteins that inhibit autophagy (shown in light blue). An important component of the complex is Vps34, a class III phosphatidylinositol 3-kinase responsible
for the formation of phosphatidylinositol-3-phosphate, which is thought to recruit autophagy-speciﬁc proteins. The anti-apoptotic protein Bcl-2 inhibits autophagy, but is
itself inhibited by phosphorylation mediated by JNK1 under starvation conditions. Two ubiquitin-like reactions contribute to the elongation of phagophores. In the ﬁrst,
Atg12 is conjugated to Atg5 via the concerted actions of Atg7 and Atg10 (E1-like and E2-like, respectively), and the resulting conjugate associates with Atg16L. This complex is
found on the outer leaf of phagophores, and dissociates from completed autophagosomes. In the second ubiquitin-like reaction, LC3 is ﬁrst trimmed by Atg4B to form LC3-I,
and is subsequently conjugated to phosphatidylethanolamine by Atg7 and Atg3 to form LC3-II. LC3-II is found on the inner and outer membranes of phagophores and
autophagosomes, and is recycled from the outer membrane of mature autolysosomes by Atg4B.
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plasma membrane in contributing to the forming phagophore
through clathrin-mediated endocytosis (Ravikumar et al., 2010a).
It is quite possible that phagophores acquire membrane from
different subcellular structures.
A critical protein regulating autophagosome formation is the
class III phosphatidylinositol 3-kinase (PI3K) Vps34, the inhibition
of which blocks autophagy (Blommaart et al., 1997) (Fig. 1). Vps34
is responsible for the formation of phosphatidylinositol-3-phos-
phate (PI-3-P). Regions in which PI-3-P is enriched may function to
recruit autophagy-speciﬁc proteins and have been found to
associate with forming phagophores (Axe et al., 2008). Vps34 is
found in a complex with other autophagy-related proteins,
including Beclin 1 (the mammalian orthologue of yeast Atg6),
p150, Barkor/Atg14, UVRAG and Ambra 1 (Kihara et al., 2001;
Itakura et al., 2008; Sun et al., 2008; Liang et al., 2008; Fimia et al.,
2007). Under non-starvation conditions, the anti-apoptotic protein
Bcl-2 binds to Beclin 1 and inhibits the formation of the Beclin 1/
Vps34 complex, thereby inhibiting autophagy (Pattingre et al.,
2005). Successful inhibition of Beclin 1 by Bcl-2 also requires
nutrient-deprivation autophagy factor-1 (NAF-1), a small integral
membrane protein in the ER (Chang et al., 2010). Upon starvation,
however, c-Jun N-terminal protein kinase 1 (JNK1) phosphorylates
Bcl-2 on multiple residues, causing it to dissociate from Beclin 1,
and allowing for the activation of autophagy (Wei et al., 2008).
In another complex, the kinase ULK1 – which localizes to
isolation membranes under starvation conditions – is also
important for autophagosome biogenesis, as its depletion com-
promises autophagy (Chan et al., 2007). Its binding partners,
FIP200 and Atg13, are responsible for the proper localization of
ULK1 to isolation membranes, and furthermore stimulate its
kinase activity (Ganley et al., 2009).
3.2.2. Elongation
While the membrane source for the growing phagophore
remains unclear, Atg9 – the only transmembrane Atg protein – has
been observed to cycle between the trans-Golgi network (TGN) and
endosomes (Young et al., 2006). Upon starvation, Atg9 redis-
tributes from the Golgi near the nucleus to the periphery, where it
colocalizes with LC3 and Atg16L, leading to speculation that Atg9
might function to deliver membrane during phagophore formation
expansion. This process requires ULK1, PI3K activity, and the
membrane curvature-driving protein Bif-1 (Takahashi et al., 2011;
Young et al., 2006).
The elongation of phagophores requires two ubiquitin-like
reactions (Fig. 1). In the ﬁrst reaction, the ubiquitin-like molecule
Atg12 is conjugated to Atg5 via an isopeptide bond through the
actions of Atg7 (E1-like enzyme) and Atg10 (E2-like enzyme)
(Mizushima et al., 1998, 2002; Tanida et al., 2001). This conjugate
associates with Atg16L and oligomerizes to form a 800 kDa
complex (Mizushima et al., 1999, 2003). The interaction of Atg5
and Atg16L is required to target the complex to autophagosome
precursors, and the presence of all three proteins is required for the
elongation of the isolation membrane. The Atg12–Atg5Atg16L
complex localizes to the outer membrane of elongating phago-
phores, but dissociates from complete autophagosomes (Mizush-
ima et al., 2003).
In the other ubiquitin-like reaction, microtubule-associated
protein 1 light chain 3 (MAP1-LC3, or simply LC3), the mammalian
orthologue of Atg8, is conjugated to phosphatidylethanolamine
(PE). First, the C-terminus of pro-LC3 is cleaved by Atg4B to expose
a conserved glycine residue and thus form LC3-I, a cytosolic form of
the protein (Hemelaar et al., 2003). Next, Atg7 acts as an activating
enzyme to form an intermediate with LC3-I (Tanida et al., 2001),
after which LC3 is transferred to the active-site cysteine of the E2-
like enzyme Atg3 and is then conjugated to PE to form membrane-
bound LC3-II (Tanida et al., 2002). LC3-II associates speciﬁcally
with autophagosome membranes and remains bound even after
fusion with lysosomes (Kabeya et al., 2000). In yeast, as well as in
mammals, LC3 has been found to promote membrane tethering
and fusion, suggesting that it enables the growth and expansion of
the forming phagophore (Nakatogawa et al., 2007; Weidberg et al.,
2011). Furthermore, LC3-II levels correlate with the number of
autophagosomes present in the cell, making it the basis for many
assays used in autophagy research (Kabeya et al., 2000; Klionsky
et al., 2008; Rubinsztein et al., 2009). Although LC3-II is found on
both sides of the autophagosome membrane, the molecules on the
outer face are eventually delipidated by Atg4B and recycled
(Tanida et al., 2004).
There is signiﬁcant cross-talk between the two ubiquitin-like
conjugation systems. In addition to the fact that the Atg16L
complex brings LC3 to the site of lipidation and acts as an E3 for
LC3-II conjugation (Fujita et al., 2008), Atg3 also facilitates the
formation of the Atg12–Atg5 conjugate (Tanida et al., 2002).
Meanwhile, Atg10, the E2-like enzyme in Atg12–Atg5 conjugation,
also facilitates the conversion of LC3 to the lipidated form,
although LC3 is not a substrate of Atg10 (Nemoto et al., 2003).
3.2.3. Maturation
In the ﬁnal steps of the autophagic pathway, autophagosomes
may fuse with endosomes, forming amphisomes (Gordon and
Seglen, 1988; Berg et al., 1998), and ultimately with lysosomes,
forming autolysosomes. To achieve this fusion, autophagosomes
move along microtubules towards lysosomes clustered at the
center of the cell using the dynein–dynactin complex (Ravikumar
et al., 2005; Jahreiss et al., 2008; Kimura et al., 2008). In fact, our
group has found that the position of lysosomes themselves
changes according to ﬂuctuations in intracellular pH, driven by
nutrient signalling. Starvation leads to increased intracellular pH,
which enhances lysosomal clustering at the perinuclear area,
putting them in the path of incoming autophagosomes and thereby
facilitating autophagosome–lysosome fusion (Korolchuk et al.,
2011). The machinery required for tethering and fusion includes
soluble N-ethylmaleimide-sensitive factor attachment protein
receptors (SNAREs) (Furuta et al., 2010). Finally, in order for the
autophagosome cargo to be degraded, lysosomal function is also
essential. The macrolide antibiotic baﬁlomycin A1 inhibits the
lysosomal proton pump and thus prevents acidiﬁcation of
lysosomes. According to electron micrograph data by Yamamoto
et al. (1998), which was later conﬁrmed with ﬂuorescent
microscopy (Jahreiss et al., 2008), this also blocks the fusion of
autophagosomes and lysosomes. In contrast, depletion of the
syntaxin-5 SNARE complex impairs the anterograde trafﬁcking of
lysosomal proteases such as cathepsins, and while it does not affect
fusion of autophagosomes with lysosomes, it does block their
degradation (Renna et al., 2011).
3.3. Signalling pathways regulating autophagy
Several signalling pathways tightly control autophagy. The
most well-known pathway involves the mammalian target of
rapamycin (mTOR) complex (Fig. 2), which inhibits autophagy, but
mTOR-independent pathways have also been recently charac-
terised.
mTOR, isolated by Sabers et al. (1995), is a large serine/
threonine protein kinase that exists in two complexes that
comprise the mTOR pathway. Its canonical role is the regulation
of cell growth and proliferation in response to nutrient conditions,
but mTOR also regulates a variety of other cellular pathways,
including autophagy, metabolism, translation, and ribosome
biogenesis (Sarbassov et al., 2005; Loewith et al., 2002). The
mTOR pathway involves two protein complexes, both of which
contain mTOR and GbL (G protein b-subunit-like protein, or
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mLST8), but differ in their other subunits (Sarbassov et al., 2005).
The rapamycin-sensitive complex, mTORC1, includes the protein
raptor and is thought to respond to nutrient conditions and
regulate autophagy (Sarbassov et al., 2005; Kim et al., 2002).
Nutrient deprivation and rapamycin inhibit mTORC1 activity (Kim
et al., 2002). The rapamycin-insensitive complex, mTORC2,
contains rictor (also known as mAVO3), and has been shown to
signal to the actin cytoskeleton, regulating actin polymerization
and cell spreading (Jacinto et al., 2004).
A wide assortment of upstream signals affects the mTOR
pathway, including glucose, amino acids and growth factors
(Sarbassov et al., 2005) (Fig. 2). Many of these, however, converge
on the tuberous sclerosis genes TSC1 and TSC2, which produce the
proteins hamartin and tuberin, respectively, and act as regulators
of mTORC1 (Tee et al., 2002). They have an inhibitory effect on
mTORC1 via the small GTPase Rheb, for which TSC2 acts as a
GTPase activating protein (Zhang et al., 2003). Under nutrient-rich
conditions, for example, insulin binds to cell-surface receptors,
activating the class I PI3K pathway, which catalyzes the conversion
of phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidyli-
nositol-3,4,5-trisphosphate (PIP3) (Petiot et al., 2000). PIP3 then
recruits proteins containing pleckstrin homology domains, includ-
ing Akt and PDK1, the latter of which contributes to phosphory-
lating Akt (Lawlor and Alessi, 2001). Akt, in turn, inhibits the TSC1/
TSC2 complex, allowing the activation of mTORC1 (Sarbassov et al.,
2005). In contrast, when the nutrient supply is low, the AMP/ATP
ratio increases, and AMP-activated kinase (AMPK) becomes active,
phosphorylating and thereby enhancing the function of TSC2
(Inoki et al., 2003). This consequently leads to the inhibition of
mTORC1 and the induction of autophagy.
In recent years, several groups have bridged the gap between
mTOR and autophagy regulation by ﬁnding that the ULK1–Atg13–
FIP200 complex is a downstream target of mTOR (Hosokawa et al.,
2009). Under nutrient-rich conditions, mTORC1 associates with
the complex and phosphorylates ULK1 and Atg13 (Hosokawa et al.,
2009). The ULK1–Atg13–FIP200 complex is essential for autopha-
gosome formation (Chan et al., 2007, 2009), and thus this
inhibitory phosphorylation suppresses autophagy (Hosokawa
et al., 2009). Recently, an mTOR-independent pathway for
activation of ULK1 has been reported. Direct phosphorylation of
ULK1 by AMPK in response to nutrient depletion leads to ULK1
activation and autophagy induction (Kim et al., 2011; Egan et al.,
2011).
In addition to the canonical mTOR pathway, autophagy can be
regulated via mTOR-independent mechanisms as well. For
example, our laboratory has elucidated a cyclical pathway
involving inositol and myoinositol-1,4,5-triphosphate (IP3), both
of which inhibit autophagy (Sarkar et al., 2005). Intracellular cAMP
acts (by means of Epac, Rap2B, and subsequently PLC-e) to increase
IP3 production (Williams et al., 2008). IP3, in turn, binds to
receptors on the ER and leads to calcium release, which activates
calpains that block autophagy (Williams et al., 2008). These
pathways will be explained in greater detail in subsequent
sections, as they were discovered and developed during the search
for novel autophagy-modulating treatments.
4. Autophagy and neurodegeneration
Autophagy appears to be crucial to prevent neurodegeneration,
even in the absence of disease-associated mutant proteins. Two
Fig. 2. Inducing autophagy by inhibiting the mTOR pathway.
mTOR is a downstream effector of the class I phosphoinositol 3-kinase (PI3K) pathway. The PI3K pathway regulates AKT phosphorylation which, in turn, inhibits the tuberous
sclerosis complex (TSC)1/2, which activates the small GTPase Rheb, resulting in mTORC1 activation. Rapamycin interacts with FKBP12 which binds to and inhibits mTORC1.
Inhibition of mTORC1 by rapamycin results in dephosphorylation-dependent activation of ULK1 and subsequent ULK1-mediated phosphorylation of Atg13, FIP200 and ULK1
itself, inducing autophagosome synthesis. The rapamycin analogue CCI-779, glucose, glucose-6-phosphate, Torin1, perhexiline, niclosamide and rottlerin also inhibit
mTORC1 activity, either directly or indirectly. Dexamethasone induces autophagy via Akt inhibition. PI103 and structurally related compounds induce autophagy by
inhibiting both PI3K and mTOR. Phenethyl isothiocyanate (PEITC) induces autophagy partially by suppressing the phosphorylation of Akt and mTOR. The vitamin E
antioxidant activates the mTOR pathway and inhibits autophagy.
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independent studies using knockout mice for Atg5 or Atg7, found
that the impaired autophagy function led to the accumulation of
ubiquitin-positive inclusions and to the development of charac-
teristic neurodegeneration phenotypes in these mice (Hara et al.,
2006; Komatsu et al., 2006). In the presence of toxic proteins,
autophagy upregulation has also been shown to be beneﬁcial. In
Alzheimer’s disease, the Ab peptide and the amyloid precursor
protein (APP)-derived fragment (APP-CTF) are cleared upon
autophagy induction (Tian et al., 2011).
Old or damaged mitochondria are less efﬁcient in producing
ATP and release greater amounts of reactive oxygen species (ROS),
the main source of oxidative stress in the cells, and one of the
hallmarks of neurodegeneration. Decreased autophagic degrada-
tion of mitochondria could therefore also constitute a key element
in neurodegenerative diseases. In this context, two proteins related
to autosomal recessive parkinsonism, PINK1 and Parkin, are
important in mitochondrial homeostasis and have been recently
implicated in the selective clearance of mitochondria by autophagy
(Narendra et al., 2008, 2010). Thus, in Parkinson’s disease,
alterations in PINK1 or Parkin may contribute to the accumulation
of dysfunctional mitochondria.
5. Autophagy implications in polyglutamine disorders
5.1. Polyglutamine-expanded proteins are substrates for autophagy
Autophagy was known since the early 1960s as a self-digestion
process necessary for the bulk degradation of cytoplasmic content
in lysosomes. It was not until 40 years later that autophagy was
implicated in the degradation of aggregate-prone proteins and
neurodegeneration. Some initial observations, such as the associ-
ation of Htt protein with vacuoles presenting autophagosomal and
autolysosomal features in a polyglutamine length-dependent
manner, suggested a possible link between autophagy and
neurodegenerative diseases (Kegel et al., 2000).
Later on, in 2002, we proposed that upregulation of autophagy
could constitute a mechanism to prevent accumulation of
aggregate-prone proteins (Ravikumar et al., 2002). We observed
that chemical blockage of autophagy, by inhibition of autophago-
some synthesis or disruption of autophagosome–lysosome fusion,
increased the levels of mutant Htt and led to the accumulation of
protein aggregates and to an exacerbation of the toxicity
associated with these aggregates. This effect was not Htt-speciﬁc
but it also reduced the number of aggregates of different
aggregate-prone protein constructs consisting of purely expanded
polyglutamines or polyalanines. Conversely, upregulating autop-
hagy with the mTOR inhibitor rapamycin resulted in reduced
aggregation and cytotoxicity (Ravikumar et al., 2002). Indeed, the
beneﬁt of rapamycin as a treatment of HD was conﬁrmed in vivo in
ﬂy and mouse models, where administration of rapamycin or its
analogues reduced the number of protein inclusions and improved
motor and behavioural test performance in these HD models
(Ravikumar et al., 2004). More recently, autophagy upregulation
has been shown to be protective in zebraﬁsh models of HD as well
(Williams et al., 2008). The beneﬁcial effects of rapamycin in these
diseases are autophagy dependent, as it has no effects in
proteionopathy ﬂy models where there is reduced activity of
autophagy genes (Berger et al., 2006; Pandey et al., 2007).
Genetic inhibition of autophagy mediated by silencing the
expression of LC3 or Atg5 (Iwata et al., 2005) or Beclin 1 (Shibata
et al., 2006) has supported the importance of autophagy in clearing
polyglutamine-expanded proteins, including full-length mutant
Huntingtin. Interestingly, chemical or genetic inhibition of
autophagy has little or no contribution to the clearance of wild-
type forms of Htt (Ravikumar et al., 2006). Moreover, an additional
cytoprotective mechanism for rapamycin was proposed, as it
protects cells and Drosophila against the toxicity of a range of pro-
apoptotic insults. Although the mechanism remains unclear, a
plausible explanation for the cytoprotective role of rapamycin
involves mitochondrial clearance by autophagy causing a reduc-
tion in cytocrome c levels and caspase activation (Ravikumar et al.,
2006).
Although initially studied in HD, the role of autophagy in
clearing other cytoplamsic polyglutamine-expanded proteins is
becoming more evident. For example, we have reported a
beneﬁcial effect of autophagy on clearance of ataxin-3, the protein
responsible for SCA3, also known as Machado-Joseph disease, the
most common type of SCA. Administration of a rapamycin
analogue, CCI-779, to a SCA3 mouse model with an expanded
ataxin-3 containing 70 glutamines (Bichelmeier et al., 2007),
reduced soluble levels of expanded ataxin-3, decreased the
number of aggregates in brains, and ameloriated motor dysfunc-
tion (Menzies et al., 2010).
In a recent study in a Drosophila model of DRPLA, where
expression of a mutant form or atrophin-1 leads to neurodegen-
eration, a dramatic increase in the number of autophagosomal
structures was observed (Nisoli et al., 2010). This suggested an
alteration of autophagy regulation upon atrophin-1 expression,
which was supported by an exacerbation of the atrophin-related
neurotoxicity when autophagy was genetically impaired. Howev-
er, when autophagy was upregulated by expression of a dominant-
negative form of TOR or treatment with rapamycin, no rescue of
the neurodegenerative phenotype in DRPLA ﬂies was achieved.
Further investigations of the autophagosome–lysosome structures
found after expression of atrophin-1, showed an increase in the
number of autophagic vesicles and autolysosomes. Although
fusion between autophagosomes and lysosomes occurred normal-
ly, lysosomal degradation was impaired. This observation explains
why induction of autophagy has no impact on aggregate clearance
in DRPLA ﬂies. Thus, in this speciﬁc polyglutamine expansion
disorder, targeting the efﬁciency of the lysosomal degradation may
be a more effective strategy for the treatment of DRPLA (Nisoli
et al., 2010).
5.2. Molecular forms of polyglutamine-expanded proteins that are
autophagy substrates
An important aspect in understanding the degradation of
polyglutamine-expanded proteins by autophagy is to discern the
molecular species that are targeted to autophagosomes for
degradation. Whether autophagy reduces the accumulation of
aggregates by engulfment of intermediate oligomeric forms or
aggregated species, or whether aggregation is reduced by
clearance of soluble proteins, thereby reducing the kinetics of
the aggregation process, remains unknown. Although it has been
reported that different autophagy proteins- LC3, Atg5, Atg12 or
Atg16L- are recruited to cytoplasmic aggregates of polyglutamines
and other aggregate-prone proteins (Iwata et al., 2005), it has not
been observed that inclusions are directly engulfed by membra-
nous vesicles. Furthermore, it should be noted that LC3 has been
found to be recruited to polyglutamine aggregates in autophagy-
deﬁcient cells and, therefore, does not necessarily reﬂect the
formation of autophagic structures (Kuma et al., 2007). Since
autophagy substrates can be cleared in cell lines without inclusions
visible by light microscopy, this suggests that autophagy can clear
monomeric or oligomeric species (Webb et al., 2003) and perhaps
the depletion of these leads to an indirect reduction of aggregate
number.
Cellular distribution of protein aggregates is also a critical
determinant when considering up regulation of autophagy as a
therapeutic strategy for these conditions. The localization of these
aggregates varies between different disorders. While in SCA1,
M. Jimenez-Sanchez et al. / Progress in Neurobiology 97 (2012) 67–82 73
SCA7, SCA17 and SBMA, aggregates accumulate in the nucleus,
they are mainly cytoplasmic in SCA2 and SCA6, or are present in
both locations in HD, SCA3, and DRPLA. This is important because
cytoplasmic forms are degraded by autophagy, while autophagic
clearance does not occur in the nucleus. Indeed, nuclear forms of
expanded ataxin-1 are not degraded via autophagy, while a mutant
form containing a defective nuclear localization signal was
successfully cleared (Iwata et al., 2005). Similarly, in SBMA, the
mutant androgen receptor binds to its ligand and is directed to the
nucleus where it aggregates and induces toxicity within motor
neurons. While autophagy can degrade cytoplasmic forms, it fails
to clear the nuclear cytotoxic species (Montie et al., 2009). The fact
that nuclear aggregates cannot be efﬁciently removed could
explain the greater toxicity associated with intranuclear inclusions
in diseases like HD where both cytoplasmic and nuclear aggregates
are present (Yang et al., 2002).
Mutant Htt, as well as androgen receptor, ataxin-3, ataxin-7 or
atrophin are targets for proteolytic cleavage by caspases, calpains,
aspartic endopeptidases or, more recently identiﬁed metallopro-
teinases (Wellington et al., 1998, 2002; Miller et al., 2010),
generating smaller N-terminal fragments containing the poly-
glutamine stretch. This proteolysis is associated with neurotoxicity
and inhibition of caspases has been shown to be beneﬁcial in
different disease models of SCA3 (Berke et al., 2004), DRPLA
(Ellerby et al., 1999), SCA7 (Garden et al., 2002) or HD (Graham
et al., 2006). The presence of these truncated forms of the protein
accelerates aggregation and inﬂuences its location. While longer
forms of mutant Htt are localized mainly in cytoplasmic
aggregates, small cleaved fragments have been shown to form
both nuclear and perinuclear inclusions. Autophagy can degrade
these N-terminal toxic forms as it has been reported for ataxin-7
(Mookerjee et al., 2009) or Htt (Ravikumar et al., 2002; Qin et al.,
2003).
5.3. Selective degradation of protein aggregates by autophagy
Until recently, autophagy was considered a bulk protein
degradation system that engulfed cytoplasmic content without
apparent speciﬁcity. However, recent data indicates that some
selectivity can enhance the degradation of damaged organelles,
invading bacteria and certain misfolded proteins. For instance,
mitochondrial degradation by autophagy in yeast has been
recently shown to involve selective targeting by Atg32. Atg32 is
a protein in the mitochondrial outer membrane that gathers other
Atg proteins to damaged mitochondria in response to oxidative
stress (Kanki et al., 2009; Okamoto et al., 2009). In higher
eukaryotes, a similar cargo receptor function for mitophagy has
been attributed to Nix/Bni3L (Schweers et al., 2007; Sandoval et al.,
2008; Novak et al., 2010).
The ubiquitin-binding protein p62/SQSTM1 is recruited into
ubiquitin-positive inclusions of tau and alpha-synuclein (Kuusisto
et al., 2001), as well as into polyglutamine aggregates (Donaldson
et al., 2003), and it has been suggested to function as a receptor for
the selective autophagic degradation of ubiquitinated substrates.
p62 contains an N-terminal PB1 domain for self-oligomerization
and several domains for interacting with different proteins
including ubiquitin, as well as LC3 (Komatsu et al., 2007; Ichimura
et al., 2008). Inhibition of autophagy led to the accumulation of p62
inclusions, suggesting, together with the fact that p62 interacts
with LC3, that p62 is an autophagic substrate. The self-oligomeri-
zation domain of p62 is required for its degradation as well as for
the formation of protein inclusions. These data support a model in
which p62 binds ubiquitinated proteins and through its self-
oligomerization domain mediates their accumulation and aggre-
gation in protein inclusions. p62 then binds and recruits LC3 to
these aggregates which are degraded in an autophagy-dependent
manner (Komatsu et al., 2007; Bjørkøy et al., 2005). While p62
depletion does not enhance mutant Htt accumulation (Korolchuk
et al., 2009), it is possible there may be redundancy in this selective
degradation system.
Alfy (autophagy-linked FYVE protein) is a PI-3-P binding
protein that interacts with LC3 and is recruited to ubiquitin
inclusions. Furthermore, it was proposed to target protein
aggregates for degradation by autophagy (Simonsen et al.,
2004). Later, it was shown that Alfy overexpression rescued
polyglutamine toxicity in cells and Drosophila and that this effect is
due to its function as an adaptor protein between p62 and
autophagy effectors (Atg5, Atg12, Atg16L1 and LC3), facilitating
autophagic degradation of p62-positive inclusions (Filimonenko
et al., 2010).
The mechanisms described above require proteins to be
polyubiquitinated prior to their degradation by autophagy. In
contrast, a novel mode of selective degradation of mutant Htt
involving previous posttranslational modiﬁcations by acetylation
has recently been suggested. In this model, polyglutamine-
expanded Htt is acetylated by CBP, which increases the rate of
degradation of the protein. Although the exact mechanism remains
unclear, the authors postulate that acetylation constitutes a signal
to target mutant protein to autophagosomes for degradation
(Jeong et al., 2009). Similarly, acetylation of lysine 257 in ataxin-7
by CBP and deacetylation by HDAC7 regulated the turnover of a
cytotoxic fragment of ataxin-7 (Mookerjee et al., 2009). However,
the consequences of this posttranslational modiﬁcation were
opposite to what was observed with mutant Htt. Ataxin-7
acetylation increased the stability of the protein and the
polyglutamine length inversely correlated with this stabilization,
providing a possible explanation for the higher toxicity of the
polyglutamine-expanded protein. They suggested that autophagy
is necessary for the clearance of the non-acetylated forms, this
effect was disrupted in the presence of the autophagy inhibitor 3-
MA but not by proteasome inhibition (Mookerjee et al., 2009).
Further studies will be necessary to clarify the roles of different
posttranslational modiﬁcations in the stability of these mutant
proteins and their and degradation by autophagy in a selective
manner.
5.4. Consequences of polyglutamine expansions on autophagic
activity
As we have discussed, it has been extensively demonstrated
that protein aggregation and cell toxicity can be slowed when
autophagy is enhanced. However, whether accumulation of
misfolded proteins is a consequence of autophagy dysregulation,
or whether autophagy is upregulated in these disorders as a
mechanism to counteract aggregate accumulation is not well
understood. A connection between mutant Htt and autophagy
alterations was described in a cellular model of HD, where
expression of an expanded Htt in mouse striatal neurons was
accompanied by an accumulation of membranes of the endosomal-
lysosomal and autophagic system (Kegel et al., 2000). Also, wild-
type Htt interacts with endosomal and autophagosomal mem-
branes (Atwal et al., 2007) and with Rab5, which is involved in
autophagosome formation (Ravikumar et al., 2008).
An upregulation of autophagy in the presence of polyglutamine
aggregates was suggested by the ﬁnding that mTOR is sequestered
into aggregates in cells expressing exogenous mutant Htt, HD
mouse models and brains of HD patients, which results in the loss
of its catalytic activity and should lead to enhanced autophago-
some formation (Ravikumar et al., 2004). However, positive
regulators of autophagy, such as Beclin 1, are also recruited into
inclusions, with negative consequences for autophagy (Shibata
et al., 2006). It is possible that autophagy levels change during the
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progression of the disease and during the different stages of the
aggregation process. Recently, the generation of a knock-in mouse
model with an early HD phenotype and early accumulation of
inclusions generated by expressing a Htt protein with 200
glutamines presented an early activation of the autophagic
response, suggesting that autophagy could be upregulated in the
initial phases of HD (Heng et al., 2010).
A recent study has suggested a novel effect of mutant Htt in
autophagy deregulation (Martinez-Vicente et al., 2010). While
they did not observe impairment in autophagosome formation or
in the levels of LC3-II in mouse embryonic ﬁbroblast (MEFs)
derived from an HD mouse model expressing the Htt protein with
111 polyglutamines, the rate of protein degradation in these cells
was reduced. The authors found that autophagosomes from HD
cells appeared relatively ‘‘empty’’ by electron microscopy and that
the content of common autophagic cargo, such as mitochondria,
polyubiquitinated proteins or lipid droplets, was reduced. Thus,
the authors suggested that mutant Htt impairs cargo recognition
by autophagosomes, which leads to a failure in protein degradation
(Martinez-Vicente et al., 2010). How the polyglutamine expansion
affects cargo recognition and whether this effect is Htt-speciﬁc or
could be extended to other polyglutamine diseases and other
proteinopathies requires further studies.
In an attempt to investigate the contribution of the poly-
glutamine expansion in disease, mice were generated where the
normal 7 glutamine repeat stretch in murine htt was replaced with
a mouse allele where the normal polyglutamine tract was
eliminated (DQ-Htt) (Zheng et al., 2010). Deletion of the
polyglutamine stretch rescued the HD phenotype caused by an
expanded allele in trans, shown by a reduction in the number of
mutant Htt aggregates, improved performance in motor and
behavioural tests, and extended the life span. This longevity effect
was observed not only when expressed in an HD model, but also in
wild-type mice, expressing DQ-Htt. We also found that these mice
had an increase in autophagy and that expression of DQ-Htt, but
not the wild-type Htt, enhanced the clearance of aggregates when
expressed in cultured cells. It seems, thus, that the polyglutamine
stretch, even when expressed at its normal length, might have
some negative effect, possibly by negatively regulating autophagy
levels (Zheng et al., 2010).
6. Modulating autophagy to treat polyglutamine diseases
Given the protective effect that autophagy exerts in a variety of
in vitro and in vivo models of polyglutamine diseases, the
identiﬁcation of strategies to induce autophagy might constitute
a viable therapeutic approach to effectively treat these conditions.
This can be achieved by enhancing autophagy via mTOR-
dependent or mTOR-independent signalling, as has been shown
with a range of autophagy modulators tested in various models of
polyglutamine diseases (Table 1).
6.1. mTOR-dependent autophagy inducers
Until recently, the only drug known to upregulate autophagy
was rapamycin, which induces autophagy by inhibiting mTOR.
Therefore, rapamycin or its analogues were initially tested as an
approach to enhance autophagic clearance of polyglutamine
expanded proteins (Ravikumar et al., 2002, 2004). Other mTOR
inhibitors have later been conﬁrmed to induce autophagy (Fig. 2).
Perhexiline, niclosamide, rottlerin and amiodarone were found in
an automated cell-based assay screen of more than 3500 chemicals
to induce autophagy via mTORC1 inhibition (Balgi et al., 2009). It
should be noted that amiodarone was found in two independent
screens of autophagy inducers. At lower concentrations, it induces
autophagy in an mTOR-independent manner via Ca2+ channels,
which will be reviewed below (Zhang et al., 2007; Williams et al.,
2008). Also, torin1, a selective ATP-competitive small molecule has
been reported to inhibit mTORC1 activity and subsequently
increase autophagy to a much greater degree than rapamycin
(Thoreen et al., 2009). As of yet, torin1 has not been tested in
models of polyglutamine disease.
Increased intracellular glucose levels have been shown to
enhance mutant Htt clearance and decrease mutant Htt aggre-
gates. This effect is mediated by glucose 6-phosphate, which
induces autophagy via mTOR inhibition (Ravikumar et al., 2003).
Autophagy induction via regulation of class I PI3K and Akt
signalling has also been reported to be mediated by the
glucocorticoid dexamethasone. In acute lymphoblastic leukaemia
and multiple myeloma cells, dexamethasone induced autophagy
through dephosphorylation and subsequent inactivation of Akt
(Fig. 2) (Laane et al., 2009; Grande´r et al., 2009). Phenethyl
isothiocyanate (PEITC), an anti-cancer agent, has been suggested to
induce Atg5-dependent autophagy. PEITC was found to increase
autophagy partially due to its ability to suppress phosphorylation
and activation of both Akt and mTOR (Bommareddy et al., 2009)
(Fig. 2).
PI103 is a selective class I PI3K inhibitor that also inhibits mTOR
in an ATP-competitive manner (Fig. 2) (Raynaud et al., 2007) and it
has been shown to be a strong inducer of autophagy (Degtyarev
et al., 2008). While PI103 itself cannot be used as an effective
therapeutic approach due to its rapid in vivo metabolism and
limited aqueous solubility (Degtyarev et al., 2008), it has been
utilised to develop other dual PI3K and mTOR inhibitors (Liu et al.,
2009a,b), which could have potential applications in treating some
diseases.
It should be noted that antioxidants, such as vitamin E, have
been considered as treatments for diseases such as HD to alleviate
the oxidative stress that is commonly associated with the
pathogenesis of neurodegeneration (Shoulson, 1998; Peyser
et al., 1995; Kamat et al., 2008). Oxidative stress occurs when
the production of ROS exceeds the capability of antioxidant
mechanisms to effectively counterbalance ROS production. How-
ever, ROS are associated with the induction of autophagy and
antioxidants can inhibit basal and induced levels of autophagy
(Scherz-Shouval et al., 2007; Underwood et al., 2010). ROS
scavengers block autophagy by increasing mTOR activity
(Fig. 2), thus it is important to consider the effects that antioxidants
may have in the induction of autophagy, specially because many
HD patients take antioxidant active supplements.
As mTOR is a central regulator of many cellular processes
(Sarbassov et al., 2005; Loewith et al., 2002) in addition to
autophagy, mTOR-inhibition may have side-effects independent of
autophagy that could limit its long-term compliance in diseases
like HD. Rapamycin is an immunosuppressive agent and impaired
wound healing and mouth ulceration are known side effects.
Therefore, we and others have tried to identify mTOR-independent
autophagy modulators.
6.2. mTOR-independent autophagy inducers
6.2.1. Regulating the phosphoinositol pathway
The ﬁrst alternative mechanism that was characterised as
increasing autophagy independently of mTOR was the reduction of
intracellular levels of inositol or (IP3) (Sarkar et al., 2005). Mood-
stabilizing drugs such as lithium, sodium valproate and carbamaz-
epine, which reduce inositol levels (Williams et al., 2002), induced
autophagic clearance of mutant Htt (Sarkar et al., 2005) (Fig. 3).
Consequently, treatment with these drugs led to a reduction of
mutant Htt aggregation in HD cell models, as well as alleviating the
disease phenotype in ﬂy models of HD (Sarkar et al., 2005, 2008;
Williams et al., 2008).
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Lithium inhibits several enzymes, including glycogen synthase
kinase-3b (GSK3b) and inositol monophosphatase (IMPase)
(Gould et al., 2002; Coyle and Duman, 2003). Lithium induces
autophagy through the inhibition of IMPase, preventing inositol
recycling downstream of IP3, which was conﬁrmed by using L-
690,330, a speciﬁc IMPase inhibitor, that has a similar effect to
lithium on the clearance of mutant proteins (Fig. 3).
Inositol-lowering drugs induce autophagy by reducing IP3 levels,
since this effect is abolished by treatments that increase IP3 levels
(Sarkar et al., 2005). IP3 can bind to IP3 receptors (IP3Rs) on the ER
causing a release in Ca2+ from ER stores (Patterson et al., 2004) and
elevated Ca2+ levels are known to inhibit autophagy (Gordon et al.,
1993) (Fig. 3). As a consequence, autophagy can be induced through
the pharmacological inhibition or genetic knockdown of IP3Rs (Fig.
3) (Criollo et al., 2007). Also, in the absence of IP3R, mitochondrial
uptake of Ca2+ is reduced and leads to the activation of AMPK
signalling and consequent induction of autophagy (Ca´rdenas et al.,
2010). The activation of AMPK mediated by lower levels of Ca2+ is
thus a very plausible mechanism accounting for the autophagy-
inducing effects of agents reducing IP3 levels.
Table 1
Autophagy modulators shown to be protective in polyglutamine disease models and their mode of action in modulating autophagy.
Autophagy Modulator Effect in polyglutamine disease 
model 
Mode of action References
(1) Rapamycin 









Enhances clearance of mutant Htt (1-4), ataxin 3 
(1, 2);  mutant Htt (1-4), and expanded polyQ  (1, 
2) aggregates;  toxicity and protective in cell (1-4), 
fly (1), mouse  (1, 2) and zebrafish (1)  HD models; 
protective in fly model of SBMA (1), flies with 
expanded polyQ (1) and mouse model of 
spinocerebellar ataxia type 3 (2). Better efficacy in 
cell and fly HD models when used with lithium (1)
mTORC1 inhibition 
Ravikumar et al., 2002, 
Ravikumar et al., 2004, 
Berger et al., 2006, 
Pandey et al., 2007, 
Ravikumar et al., 2003, 
Underwood et al., 2010, 
Menzies et al., 2010, 
Sarkar, Krishna et al., 2008, 
Thoreen et al., 2009, 
Balgi et al., 2009
(9) PI103 and structurally 
related compounds - Dual PI3K and mTOR inhibitor Degtyarev et al., 2008 
(10) Phenethyl
isothiocyanate (PEITC) - 
Supresses phosphorylation of Akt 
and mTOR
Bommareddy et al., 2009
(11) Dexamethasone - Glucocorticoid, mTOR inhibition by
upregulating Akt dephosphorylation 
Laane et al., 2009, 
Grandér et al., 2009 
(12) Lithium
(13) L-690,330
Enhances clearance of mutant Htt (12, 13); 
 mutant Htt aggregates (12, 13); 
 toxicity and protective in cell (12, 13) and fly (12)
HD models.  Better efficacy in cell and fly HD 
models when used with rapamycin (12)
Inhibits IMPase and inositol and IP3
levels; mTOR-independent 
Sarkar et al., 2005
Sarkar et al., 2008
(14) Sodium Valproate 
(15) Carbamazepine 
Enhances clearance of mutant Htt (14, 15); 
 mutant Htt aggregates (14, 15);  toxicity and 
protective in cell (14, 15) and fly (14) HD models 
inositol and IP3 levels; mTOR 
independent 
Sarkar et al., 2005
Williams et al., 2008 
(16) Clonidine 
(17) Rilminidine 
Enhances clearance of mutant Htt (16, 17); 
 mutant Htt aggregates (16, 17); protective in cell 
(16, 17), fly (16) and zebrafish (16) and mouse (17) 
HD models 
Imidazoline-1 receptor agonist 
causing in cAMP; mTOR 
independent 
Williams et al., 2008 
Underwood et al., 2010 
Rose et al., 2010
(18) 2’- 5’-dideoxyadenosine 
Enhances clearance of mutant Htt ; mutant Htt 
aggregates, protective in cell and zebrafish HD 
models (18)
Inhibits adenyl cyclase causing in 
cAMP; mTOR independent 








Enhances clearance of mutant Htt (19-21, 24-25); 
mutant Htt (19-21, 24-25) and expanded polyQ 
aggregates (20-23); protective in cell (19-21, 24-
25), fly (19)  and zebrafish (19) HD models 
L-type Ca
2+
 channel antagonists; 
mTOR independent 
* Amiodarone has also been
suggested to inhibit mTORC1 
Williams et al., 2008 
Zhang et al., 2007 
Balgi et al., 2009
(26) Calpastatin 
(27) Calpeptin
Enhances clearance of mutant Htt (26, 27); 
 mutant Htt aggregates (26, 27); protective in cell 
(26, 27) and zebrafish (26) HD models 
Calpain inhibitor; mTOR independent Williams et al., 2008 




(32) 18 SMER analogues
Enhances clearance of mutant Htt (29-32); 
 mutant Htt aggregates (29-32); protective in cell 
and fly HD models (29-31)
Unknown mechanism; mTOR 
independent 
Sarkar et al., 2007
(33) Fluspirilene 
(34) Trifluoperazine  expanded polyQ aggregates in cells (33-34)
Dopamine antagonists; mTOR 
independent 
Zhang et al., 2007 
(35) Penitrem A  expanded polyQ aggregates in cells (35)
Inhibits high conductance Ca
2+
activated K+ channels; mTOR 
independent 
Zhang et al., 2007 
(36) Trehalose
Enhances clearance of mutant Htt; mutant Htt 
aggregates; protective in cell and mouse HD 
models (36)
Unknown mechanism; mTOR 
independent 
Sarkar et al., 2006 
Tanaka et al.. 2004
(37) Minoxidil Enhances clearance of mutant Htt; mutant Htt 




ATP channel opener; mTOR
independent 
Williams et al., 2008 
In green, autophagy inducers; in blue, autophagy modulators to be investigated further in polyglutamine disease models; ", increase; #, decrease.
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6.2.2. Regulating the cAMP-Epac-PLC-e pathway
In order to identify new mTOR-independent pathways to
induce autophagy, we carried out a screen of 253 compounds
comprising FDA-approved drugs and pharmacologically active
compounds, analysing the effects of these drugs on the clearance of
mutant Htt (Williams et al., 2008). Clonidine, an imidazoline-1
receptor (I1R) agonist, was identiﬁed in this screen as an mTOR-
independent autophagy enhancer that increased clearance of
mutant Htt. This drug, as well as rilmenidine (another clinically
approved drug), enhances autophagy by lowering cAMP levels
through its I1R agonist activity (Fig. 3) (Williams et al., 2008).
Along the same lines, reducing cAMP levels by inhibiting adenylyl
cyclase through 20,50-dideoxyadenosine also increased autophagy.
cAMP regulates autophagy through Epac-PLCe signalling, which
converges on the modulation of IP3 levels (Fig. 3).
Both clonidine and rilmenidine have been shown to induce
autophagy and enhance the clearance of mutant Htt (Williams
et al., 2008; Rose et al., 2010). Clonidine and 2050-dideoxyadenosine
are protective in zebraﬁsh models of HD and clonidine has also
been shown to be protective in cells and ﬂies expressing the
mutant Htt protein (Williams et al., 2008). Recently, we reported
the ability of rilmenidine to attenuate the disease phenotype in a
mouse model of HD by reducing levels of mutant Htt fragments via
the activation of autophagy (Rose et al., 2010). In safety trials,
rilmenidine did not show an excess of adverse side effects when
compared to placebo (Yu and Frishman, 1996). This indicates the
possibility of using cAMP modulators to treat polyglutamine
diseases, as many of them are already well-tolerated drugs used for
the treatment of other conditions.
6.2.3. Regulating the Ca2+-calpain-GSa pathway
In the same screen that identiﬁed clonidine as an autophagy
enhancer, the L-type Ca2+ channel antagonists verapamil, loper-
amide, amiodarone, nimodipine and nitrendipine were identiﬁed
to enhance autophagic clearance of mutant Htt proteins (Williams
et al., 2008). When binding to L-type Ca2+ channels, these drugs
prevent the inﬂux of Ca2+ into the cell, and thus decrease the
intracellular levels of Ca2+, resulting in increased autophagy, as
previously reported (Fig. 3) (Gordon et al., 1993). The Ca2+ channel
blockers niguldipine and pimozide (along with loperamide and
amiodarone) were identiﬁed as autophagy enhancers in another
screen analysing the effect of drug treatment on the number of
GFP-LC3 vesicles in cells (taken to be a readout of autophagy)
(Zhang et al., 2007). Rises in intracellular Ca2+ levels activate
calpain activity, and calpain inhibition has also been shown in this
screen to activate autophagy (Williams et al., 2008) (Fig. 3).
Fig. 3. Inducing autophagy independent of the mTOR pathway.
The cyclical mTOR-independent pathway consists of the cAMP-Epac-PLC-e, phosphoinositol and Ca2+-calpain-GSa pathways and has multiple points where it can be
modulated to induce autophagy in order to treat polyglutamine diseases. Intracellular cAMP levels are increased by adenylyl cyclase (AC), which activates Epac, which in
turn activates the small G-protein Rap2B that activates phospholipase C (PLC)-e. PLC-e activation results in the production of IP3 from phosphatidylinositol 4,5-
bisphosphate (PIP2) and IP3 binds to the endoplasmic reticulum (ER) IP3Rs releasing Ca
2+ from ER Ca2+ stores. Intracytosolic Ca2+ levels are also increased by Ca2+ inﬂux due
to L-type Ca2+ channel agonist binding. Increase in intracytosolic Ca2+ activates the cysteine protease calpains which cleave and activate GSa. GSa activation results in an
increase in AC activity elevating cAMP levels, therefore as part of a loop. Activation of this loop pathway inhibits autophagy. Drugs targeting targets at different stages
within the loop can induce autophagy and are protective in various polyglutamine disease models such as: imidazoline-1-receptor (I1R) agonists (clonidine and
rilmenidine) and the AC inhibitor 20 ,50-dideoxyadenosine (2050ddA) that act to decrease cAMP levels; agents that reduce inositol and IP3 levels (lithium, L-690,330, sodium
valproate and carbamazepine); Ca2+ channel blockers (verapamil, loperamide, amiodarone, nimodipine, nitrendipine, niguldipine and pimozide); calpain inhibitors
(calpastatin and calpeptin) and the GSa inhibitor NF449. JNK phosphorylation of Bcl-2 results in the dissociation of Bcl-2 from Beclin 1 causing an induction of autophagy.
The thiol antioxidants N-acetyl cysteine (NAC) and glutathione inhibit JNK activation and thus inhibit the phosphorylation of Bcl-2 resulting in the inhibition of autophagy
as shown in cell, ﬂy and zebraﬁsh models of HD.
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6.2.4. Other mTOR-independent mechanisms
Trehalose, a dissacharide, is another mTOR-independent
autophagy inducer (Table 1). It also acts as a chemical chaperone
able to inﬂuence protein folding and aggregation through protein–
trehalose interactions (Davies et al., 2006; Chen and Haddad, 2004;
Sarkar et al., 2007a). Trehalose has been reported to reduce mutant
Htt aggregation and toxicity in cell models of HD and attenuate
disease pathology in a mouse model of HD via its chemical
chaperone activity (Tanaka et al., 2004). Meanwhile, it can also
enhance clearance of mutant aggregate-prone mutant Htt and
protect against apoptotic insults in cells via its autophagy-inducing
properties (Sarkar et al., 2007a). Thus, the additive effects of its
autophagy-inducing and chemical chaperone activities, coupled
with its lack of toxicity, suggest trehalose could be of potential
beneﬁt in the treatment of polyglutamine diseases.
A screen in yeast with 50,729 compounds was carried out to
identify small molecule chemical modiﬁers of the cytostatic effects
of rapamycin (Sarkar et al., 2007b). Small molecule enhancers of
rapamycin (SMERs) and small molecule inhibitors of rapamycin
(SMIRs) were tested in a secondary screen for their effects on
autophagy that were independent of rapamycin. Three SMERs
were identiﬁed as inducers of autophagy, which enhanced the
clearance of mutant Htt fragments, reduced mutant Htt aggrega-
tion and were protective in cell and ﬂy models of HD:SMER10,
SMER18, and SMER28 (Table 1). The autophagy-inducing effects of
these SMERs were indicated as being independent of mTOR, and 18
structural analogues were identiﬁed to also enhance the clearance
of mutant Htt aggregate-prone proteins (Sarkar et al., 2007b).
Another screen identiﬁed ﬂuspirilene and triﬂuoperazine
(dopamine antagonists) and penitrem A (inhibitor of high
conductance Ca2+-activated K+ channels) as autophagy enhancers
(Zhang et al., 2007). They were found to reduce the number of
expanded polyglutamine aggregates by increasing autophagy
independently of mTOR (Table 1).
6.3. Combination treatment approaches that induce autophagy
Rapamycin or other mTOR inhibitors can be combined
effectively with mTOR-independent inducers, such as trehalose,
calpastatin and the SMERs, to enhance autophagic clearance of
aggregate-prone proteins (Williams et al., 2008; Sarkar et al.,
2007a,b). Combination treatment consisting of lithium or L-
690,330 with rapamycin results in enhanced clearance of mutant
Htt and enhanced protective effects in cell and ﬂy models of HD,
compared to treatment with either drug alone (Sarkar et al., 2005,
2008), These effects are due to the additive effects of mTOR
inhibition (by rapamycin) and the mTOR-independent phosphoi-
nositol pathway regulation (by lithium and L-690,330) in
enhancing autophagy (Sarkar et al., 2005). Indeed, treatment of
heterozygous TOR mutant ﬂies (with impaired TOR activity)
expressing mutant Htt with lithium shows higher neuroprotec-
tion when compared to non-treated heterozygous ﬂies (Sarkar
et al., 2008). In addition, lithium is also known to inhibit GSK-3b,
which results in mTOR activation, which would inhibit autophagy
(Inoki et al., 2006; Sarkar et al., 2008). Combination of lithium
with rapamycin would help to counteract the undesired inhibi-
tion of autophagy resulting from GSK-3b activation (Sarkar et al.,
2008). Lithium and rapamycin combination treatment of poly-
glutamine diseases is also attractive due to the additional
protective effects that lithium GSK-3b inhibition has by exerting
cytoprotective effects due to activation of the b-catenin/Tcf
pathway (Carmichael et al., 2002; Berger et al., 2005; Sarkar et al.,
2008).
These combination treatments are potentially desirable not
only because of their additive effects in autophagic clearance of
mutant proteins, but also due to the compensatory effect one drug
may have for any unwanted side effects of the other drug
that result from non-speciﬁc actions on alternative signalling
processes. Therefore, one may be able to use lower doses of
the respective drugs to achieve sufﬁcient levels of autophagy
induction, to achieve higher efﬁcacy with minimal unwanted side
effects. Further demonstration of combination strategies in animal
polyglutamine disease models is required.
6.4. Future therapeutic prospects
Autophagy interacts with other cellular processes associated
with neurodegeneration in polygutamine diseases and a greater
understanding of this relationship is vital for determining the most
effective treatment strategies. For example, the oxidative stress
associated with HD can be targeted by antioxidant treatment in HD
patients but, as we have shown, antioxidants can inhibit the basal
and induced levels of autophagy (Underwood et al., 2010).
Therefore, it is important to further test combinations of
autophagy-inducing modulators with other polyglutamine disease
treatments targeting different cellular processes associated with
disease pathology.
In addition to this, it is obvious that early drug administration is
key to effective treatment. Indeed, with monogenic diseases like
polyglutamine diseases, most cases will have a family history and
thus it is possible to treat patients at risk with pre-symptomatic
treatment. Thus, better understanding of how diseases affect
autophagy and how autophagy modulators may beneﬁt disease
may have clinical impact.
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